Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1998 Nov;228(5):638–651. doi: 10.1097/00000658-199811000-00003

Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk.

I A Mustafa 1, K I Bland 1
PMCID: PMC1191569  PMID: 9833802

Abstract

Most data demonstrate that breast cancer is hormonally influenced. For the woman with no history of breast cancer, the benefits of HRT may outweigh the risks. Although it remains the standard of care to discourage hormone use in patients who have had breast cancer, future studies may result in a change of this standard. There needs to be more research into these complex hormonal interactions so that we will have a better understanding of the true risks and benefits when we attempt to advise our patients regarding the best treatment regimens for them.

Full text

PDF
640

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrektsen G., Heuch I., Kvåle G. The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer. 1995 Aug;72(2):480–484. doi: 10.1038/bjc.1995.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allegra J. C., Kiefer S. M. Mechanisms of action of progestational agents. Semin Oncol. 1985 Mar;12(1 Suppl 1):3–5. [PubMed] [Google Scholar]
  3. Ariel I. M., Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg. 1989 Jul-Sep;74(3):185–187. [PubMed] [Google Scholar]
  4. Armstrong B. K. Oestrogen therapy after the menopause--boon or bane? Med J Aust. 1988 Mar 7;148(5):213–214. doi: 10.5694/j.1326-5377.1988.tb99424.x. [DOI] [PubMed] [Google Scholar]
  5. Bagdade J. D., Wolter J., Subbaiah P. V., Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab. 1990 Apr;70(4):1132–1135. doi: 10.1210/jcem-70-4-1132. [DOI] [PubMed] [Google Scholar]
  6. Bergkvist L., Adami H. O., Persson I., Bergström R., Krusemo U. B. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989 Aug;130(2):221–228. doi: 10.1093/oxfordjournals.aje.a115328. [DOI] [PubMed] [Google Scholar]
  7. Bertelli G., Pronzato P., Amoroso D., Cusimano M. P., Conte P. F., Montagna G., Bertolini S., Rosso R. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988 Dec;12(3):307–310. doi: 10.1007/BF01811244. [DOI] [PubMed] [Google Scholar]
  8. Bhatia N. N., Bergman A., Karram M. M. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol. 1989 Jan;160(1):176–181. doi: 10.1016/0002-9378(89)90114-2. [DOI] [PubMed] [Google Scholar]
  9. Bland K. I., Buchanan J. B., Weisberg B. F., Hagan T. A., Gray L. A., Sr The effects of exogenous estrogen replacement therapy of the breast: breast cancer risk and mammographic parenchymal patterns. Cancer. 1980 Jun 15;45(12):3027–3033. doi: 10.1002/1097-0142(19800615)45:12<3027::aid-cncr2820451225>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  10. Boice J. D., Jr, Monson R. R. Breast cancer in women after repeated fluoroscopic examinations of the chest. J Natl Cancer Inst. 1977 Sep;59(3):823–832. doi: 10.1093/jnci/59.3.823. [DOI] [PubMed] [Google Scholar]
  11. Bonnier P., Romain S., Giacalone P. L., Laffargue F., Martin P. M., Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 1995 Jan;85(1):11–17. doi: 10.1016/0029-7844(94)00324-7. [DOI] [PubMed] [Google Scholar]
  12. Borg A., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Olsson H., Killander D., McGurie W. L. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer. 1991 Jan;63(1):136–142. doi: 10.1038/bjc.1991.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Christiansen C., Christensen M. S., McNair P., Hagen C., Stocklund K. E., Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980 Aug;10(4):273–279. doi: 10.1111/j.1365-2362.1980.tb00033.x. [DOI] [PubMed] [Google Scholar]
  14. Chung M., Chang H. R., Bland K. I., Wanebo H. J. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996 Jan 1;77(1):97–103. doi: 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  15. Cobleigh M. A., Berris R. F., Bush T., Davidson N. E., Robert N. J., Sparano J. A., Tormey D. C., Wood W. C. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA. 1994 Aug 17;272(7):540–545. [PubMed] [Google Scholar]
  16. Col N. F., Eckman M. H., Karas R. H., Pauker S. G., Goldberg R. J., Ross E. M., Orr R. K., Wong J. B. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997 Apr 9;277(14):1140–1147. [PubMed] [Google Scholar]
  17. Colditz G. A., Stampfer M. J., Willett W. C., Hennekens C. H., Rosner B., Speizer F. E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990 Nov 28;264(20):2648–2653. [PubMed] [Google Scholar]
  18. Cooper D. R., Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg. 1970 Mar;171(3):429–433. doi: 10.1097/00000658-197003000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Couzi R. J., Helzlsouer K. J., Fetting J. H. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995 Nov;13(11):2737–2744. doi: 10.1200/JCO.1995.13.11.2737. [DOI] [PubMed] [Google Scholar]
  20. De Waard F. Preventive intervention in breast cancer, but when? Eur J Cancer Prev. 1992 Oct;1(6):395–399. doi: 10.1097/00008469-199210000-00001. [DOI] [PubMed] [Google Scholar]
  21. Dewar J. A., Horobin J. M., Preece P. E., Tavendale R., Tunstall-Pedoe H., Wood R. A. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992 Jul 25;305(6847):225–226. doi: 10.1136/bmj.305.6847.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. DiSaia P. J. Hormone-replacement therapy in patients with breast cancer. A reappraisal. Cancer. 1993 Feb 15;71(4 Suppl):1490–1500. doi: 10.1002/cncr.2820710414. [DOI] [PubMed] [Google Scholar]
  23. Donegan W. L. Breast cancer and pregnancy. Obstet Gynecol. 1977 Aug;50(2):244–252. [PubMed] [Google Scholar]
  24. Dupont W. D., Page D. L., Rogers L. W., Parl F. F. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer. 1989 Mar 1;63(5):948–957. doi: 10.1002/1097-0142(19890301)63:5<948::aid-cncr2820630527>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  25. Ernster V. L., Bush T. L., Huggins G. R., Hulka B. S., Kelsey J. L., Schottenfeld D. Benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med. 1988 Mar;17(2):201–223. doi: 10.1016/0091-7435(88)90064-3. [DOI] [PubMed] [Google Scholar]
  26. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  27. Fornander T., Rutqvist L. E., Sjöberg H. E., Blomqvist L., Mattsson A., Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol. 1990 Jun;8(6):1019–1024. doi: 10.1200/JCO.1990.8.6.1019. [DOI] [PubMed] [Google Scholar]
  28. Gambrell R. D., Jr Prevention of endometrial cancer with progestogens. Maturitas. 1986 Jul;8(2):159–168. doi: 10.1016/0378-5122(86)90022-8. [DOI] [PubMed] [Google Scholar]
  29. Gambrell R. D., Jr Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol. 1984 Sep 15;150(2):119–132. doi: 10.1016/s0002-9378(84)80002-2. [DOI] [PubMed] [Google Scholar]
  30. Gapstur S. M., Potter J. D., Drinkard C., Folsom A. R. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):313–318. [PubMed] [Google Scholar]
  31. Gapstur S. M., Potter J. D., Sellers T. A., Folsom A. R. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol. 1992 Nov 15;136(10):1221–1231. doi: 10.1093/oxfordjournals.aje.a116430. [DOI] [PubMed] [Google Scholar]
  32. Gompel A., Malet C., Spritzer P., Lalardrie J. P., Kuttenn F., Mauvais-Jarvis P. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab. 1986 Nov;63(5):1174–1180. doi: 10.1210/jcem-63-5-1174. [DOI] [PubMed] [Google Scholar]
  33. Grady D., Rubin S. M., Petitti D. B., Fox C. S., Black D., Ettinger B., Ernster V. L., Cummings S. R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992 Dec 15;117(12):1016–1037. doi: 10.7326/0003-4819-117-12-1016. [DOI] [PubMed] [Google Scholar]
  34. Grodstein F., Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Joffe M., Rosner B., Fuchs C., Hankinson S. E., Hunter D. J. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997 Jun 19;336(25):1769–1775. doi: 10.1056/NEJM199706193362501. [DOI] [PubMed] [Google Scholar]
  35. Grodstein F., Stampfer M. J., Manson J. E., Colditz G. A., Willett W. C., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996 Aug 15;335(7):453–461. doi: 10.1056/NEJM199608153350701. [DOI] [PubMed] [Google Scholar]
  36. HOLLEB A. I., FARROW J. H. The relation of carcinoma of the breast and pregnancy in 283 patients. Surg Gynecol Obstet. 1962 Jul;115:65–71. [PubMed] [Google Scholar]
  37. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol. 1992 Jun;166(6 Pt 2):1986–1992. doi: 10.1016/0002-9378(92)91399-u. [DOI] [PubMed] [Google Scholar]
  38. Harvey J. C., Rosen P. P., Ashikari R., Robbins G. F., Kinne D. W. The effect of pregnancy on the prognosis of carcinoma of the breast following radical mastectomy. Surg Gynecol Obstet. 1981 Nov;153(5):723–725. [PubMed] [Google Scholar]
  39. Helzlsouer K. J., Couzi R. Hormones and breast cancer. Cancer. 1995 Nov 15;76(10 Suppl):2059–2063. doi: 10.1002/1097-0142(19951115)76:10+<2059::aid-cncr2820761325>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  40. Henderson B. E., Paganini-Hill A., Ross R. K. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991 Jan;151(1):75–78. [PubMed] [Google Scholar]
  41. Henderson B. E., Ross R. K., Pike M. C. Hormonal chemoprevention of cancer in women. Science. 1993 Jan 29;259(5095):633–638. doi: 10.1126/science.8381558. [DOI] [PubMed] [Google Scholar]
  42. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  43. Heuson J. C. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep. 1976 Oct;60(10):1463–1466. [PubMed] [Google Scholar]
  44. Holmes W. E., Sliwkowski M. X., Akita R. W., Henzel W. J., Lee J., Park J. W., Yansura D., Abadi N., Raab H., Lewis G. D. Identification of heregulin, a specific activator of p185erbB2. Science. 1992 May 22;256(5060):1205–1210. doi: 10.1126/science.256.5060.1205. [DOI] [PubMed] [Google Scholar]
  45. Hui S. L., Slemenda C. W., Johnston C. C., Jr Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med. 1989 Sep 1;111(5):355–361. doi: 10.7326/0003-4819-111-5-355. [DOI] [PubMed] [Google Scholar]
  46. Hulka B. S., Liu E. T., Lininger R. A. Steroid hormones and risk of breast cancer. Cancer. 1994 Aug 1;74(3 Suppl):1111–1124. doi: 10.1002/1097-0142(19940801)74:3+<1111::aid-cncr2820741520>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  47. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987 Jul;94(7):620–635. doi: 10.1111/j.1471-0528.1987.tb03166.x. [DOI] [PubMed] [Google Scholar]
  48. Hunter D. J., Willett W. C. Nutrition and breast cancer. Cancer Causes Control. 1996 Jan;7(1):56–68. doi: 10.1007/BF00115638. [DOI] [PubMed] [Google Scholar]
  49. Jensen G. F., Christiansen C., Boesen J., Hegedüs V., Transbøl I. Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res. 1982 Jun;(166):75–81. [PubMed] [Google Scholar]
  50. King R. M., Welch J. S., Martin J. K., Jr, Coulam C. B. Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet. 1985 Mar;160(3):228–232. [PubMed] [Google Scholar]
  51. Koh K. K., Mincemoyer R., Bui M. N., Csako G., Pucino F., Guetta V., Waclawiw M., Cannon R. O., 3rd Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997 Mar 6;336(10):683–690. doi: 10.1056/NEJM199703063361002. [DOI] [PubMed] [Google Scholar]
  52. Korenman S. G. The endocrinology of breast cancer. Cancer. 1980 Aug 15;46(4 Suppl):874–878. doi: 10.1002/1097-0142(19800815)46:4+<874::aid-cncr2820461305>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  53. Laya M. B., Larson E. B., Taplin S. H., White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 1996 May 15;88(10):643–649. doi: 10.1093/jnci/88.10.643. [DOI] [PubMed] [Google Scholar]
  54. Legha S. S., Carter S. K. Antiestrogens in the treatment of breast cancer. Cancer Treat Rev. 1976 Dec;3(4):205–216. doi: 10.1016/s0305-7372(76)80010-2. [DOI] [PubMed] [Google Scholar]
  55. Lidereau R., Callahan R., Dickson C., Peters G., Escot C., Ali I. U. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res. 1988 Feb;2(3):285–291. [PubMed] [Google Scholar]
  56. Lindsay R., Hart D. M., Clark D. M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984 Jun;63(6):759–763. [PubMed] [Google Scholar]
  57. Lippman M., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976 Dec;36(12):4595–4601. [PubMed] [Google Scholar]
  58. Love R. R., Mazess R. B., Barden H. S., Epstein S., Newcomb P. A., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992 Mar 26;326(13):852–856. doi: 10.1056/NEJM199203263261302. [DOI] [PubMed] [Google Scholar]
  59. Lubin F., Ruder A. M., Wax Y., Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. A case-control study. Am J Epidemiol. 1985 Oct;122(4):579–588. doi: 10.1093/oxfordjournals.aje.a114137. [DOI] [PubMed] [Google Scholar]
  60. Lubin F., Ruder A. M., Wax Y., Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. A case-control study. Am J Epidemiol. 1985 Oct;122(4):579–588. doi: 10.1093/oxfordjournals.aje.a114137. [DOI] [PubMed] [Google Scholar]
  61. Manni A., Pearson O. H. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):779–785. [PubMed] [Google Scholar]
  62. Markopoulos C., Berger U., Wilson P., Gazet J. C., Coombes R. C. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed) 1988 May 14;296(6633):1349–1351. doi: 10.1136/bmj.296.6633.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Marshall W. A., Tanner J. M. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291–303. doi: 10.1136/adc.44.235.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. McDonald C. C., Stewart H. J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991 Aug 24;303(6800):435–437. doi: 10.1136/bmj.303.6800.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Mehta R. R., Valcourt L., Graves J., Green R., Das Gupta T. K. Subcellular concentrations of estrone, estradiol, androstenedione and 17 beta-hydroxysteroid dehydrogenase (17-beta-OH-SDH) activity in malignant and non-malignant human breast tissues. Int J Cancer. 1987 Sep 15;40(3):305–308. doi: 10.1002/ijc.2910400304. [DOI] [PubMed] [Google Scholar]
  66. Melbye M., Wohlfahrt J., Olsen J. H., Frisch M., Westergaard T., Helweg-Larsen K., Andersen P. K. Induced abortion and the risk of breast cancer. N Engl J Med. 1997 Jan 9;336(2):81–85. doi: 10.1056/NEJM199701093360201. [DOI] [PubMed] [Google Scholar]
  67. Mignot L., Morvan F., Berdah J., Querleu D., Laurent J. C., Verhaeghe M., Fontaine F., Marin J. L., Gorins A., Marty M. Grossesses après cancer du sein traité. Résultats d'une étude cas-témoins. Presse Med. 1986 Nov 8;15(39):1961–1964. [PubMed] [Google Scholar]
  68. Nachtigall M. J., Smilen S. W., Nachtigall R. D., Nachtigall R. H., Nachtigall L. E. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol. 1992 Nov;80(5):827–830. [PubMed] [Google Scholar]
  69. Nilsson K., Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study. Maturitas. 1992 Oct;15(2):121–127. doi: 10.1016/0378-5122(92)90246-z. [DOI] [PubMed] [Google Scholar]
  70. Nugent P., O'Connell T. X. Breast cancer and pregnancy. Arch Surg. 1985 Nov;120(11):1221–1224. doi: 10.1001/archsurg.1985.01390350007001. [DOI] [PubMed] [Google Scholar]
  71. Peles E., Bacus S. S., Koski R. A., Lu H. S., Wen D., Ogden S. G., Levy R. B., Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992 Apr 3;69(1):205–216. doi: 10.1016/0092-8674(92)90131-u. [DOI] [PubMed] [Google Scholar]
  72. Preston-Martin S., Pike M. C., Ross R. K., Henderson B. E. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Prog Clin Biol Res. 1991;369:21–34. [PubMed] [Google Scholar]
  73. Ravdin R. G., Lewison E. F., Slack N. H., Dao T. L., Gardner B., State D., Fisher B. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet. 1970 Dec;131(6):1055–1064. [PubMed] [Google Scholar]
  74. Rigg L. A., Hermann H., Yen S. S. Absorption of estrogens from vaginal creams. N Engl J Med. 1978 Jan 26;298(4):195–197. doi: 10.1056/NEJM197801262980406. [DOI] [PubMed] [Google Scholar]
  75. Riis B. J., Thomsen K., Strøm V., Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol. 1987 Jan;156(1):61–65. doi: 10.1016/0002-9378(87)90203-1. [DOI] [PubMed] [Google Scholar]
  76. Rissanen P. M. Pregnancy following treatment of mammary carcinoma. Acta Radiol Ther Phys Biol. 1969 Oct;8(5):415–422. doi: 10.3109/02841866909134468. [DOI] [PubMed] [Google Scholar]
  77. Rosner D., Lane W. W. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer. 1986 Feb 1;57(3):591–596. doi: 10.1002/1097-0142(19860201)57:3<591::aid-cncr2820570333>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  78. Ross P. D., Davis J. W., Epstein R. S., Wasnich R. D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919–923. doi: 10.7326/0003-4819-114-11-919. [DOI] [PubMed] [Google Scholar]
  79. Rutqvist L. E., Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993 Sep 1;85(17):1398–1406. doi: 10.1093/jnci/85.17.1398. [DOI] [PubMed] [Google Scholar]
  80. Sawka C. A., Pritchard K. I., Paterson A. H., Sutherland D. J., Thomson D. B., Shelley W. E., Myers R. E., Mobbs B. G., Malkin A., Meakin J. W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 1986 Jun;46(6):3152–3156. [PubMed] [Google Scholar]
  81. Schiff I., Tulchinsky D., Cramer D., Ryan K. J. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA. 1980 Sep 26;244(13):1443–1445. [PubMed] [Google Scholar]
  82. Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975 Dec 4;293(23):1164–1167. doi: 10.1056/NEJM197512042932302. [DOI] [PubMed] [Google Scholar]
  83. Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. doi: 10.1016/0091-7435(91)90006-p. [DOI] [PubMed] [Google Scholar]
  84. Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991 Sep 12;325(11):756–762. doi: 10.1056/NEJM199109123251102. [DOI] [PubMed] [Google Scholar]
  85. Stanford J. L., Weiss N. S., Voigt L. F., Daling J. R., Habel L. A., Rossing M. A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995 Jul 12;274(2):137–142. [PubMed] [Google Scholar]
  86. Steinberg K. K., Thacker S. B., Smith S. J., Stroup D. F., Zack M. M., Flanders W. D., Berkelman R. L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991 Apr 17;265(15):1985–1990. [PubMed] [Google Scholar]
  87. Steingold K. A., Laufer L., Chetkowski R. J., DeFazio J. D., Matt D. W., Meldrum D. R., Judd H. L. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab. 1985 Oct;61(4):627–632. doi: 10.1210/jcem-61-4-627. [DOI] [PubMed] [Google Scholar]
  88. Stoll B. A. Effect of Lyndiol, an oral contraceptive, on breast cancer. Br Med J. 1967 Jan 21;1(5533):150–153. doi: 10.1136/bmj.1.5533.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Stoll B. A. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1909–1913. doi: 10.1016/0277-5379(89)90372-6. [DOI] [PubMed] [Google Scholar]
  90. Stoll B. A., Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet. 1988 Jun 4;1(8597):1278–1279. doi: 10.1016/s0140-6736(88)92096-x. [DOI] [PubMed] [Google Scholar]
  91. Strickland D. M., Gambrell R. D., Jr, Butzin C. A., Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol. 1992 Sep;80(3 Pt 1):400–404. [PubMed] [Google Scholar]
  92. Sutton R., Buzdar A. U., Hortobagyi G. N. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990 Feb 15;65(4):847–850. doi: 10.1002/1097-0142(19900215)65:4<847::aid-cncr2820650402>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  93. Tokunaga M., Norman J. E., Jr, Asano M., Tokuoka S., Ezaki H., Nishimori I., Tsuji Y. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst. 1979 Jun;62(6):1347–1359. [PubMed] [Google Scholar]
  94. Turken S., Siris E., Seldin D., Flaster E., Hyman G., Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989 Jul 19;81(14):1086–1088. doi: 10.1093/jnci/81.14.1086. [DOI] [PubMed] [Google Scholar]
  95. Wild R. A. Estrogen: effects on the cardiovascular tree. Obstet Gynecol. 1996 Feb;87(2 Suppl):27S–35S. doi: 10.1016/0029-7844(95)00434-3. [DOI] [PubMed] [Google Scholar]
  96. Wile A. G., Opfell R. W., Margileth D. A. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg. 1993 Mar;165(3):372–375. doi: 10.1016/s0002-9610(05)80848-7. [DOI] [PubMed] [Google Scholar]
  97. Wilson P. D., Faragher B., Butler B., Bu'Lock D., Robinson E. L., Brown A. D. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol. 1987 Jun;94(6):568–574. doi: 10.1111/j.1471-0528.1987.tb03152.x. [DOI] [PubMed] [Google Scholar]
  98. Wingo P. A., Layde P. M., Lee N. C., Rubin G., Ory H. W. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987 Jan 9;257(2):209–215. [PubMed] [Google Scholar]
  99. Wingo P. A., Lee N. C., Ory H. W., Beral V., Peterson H. B., Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol. 1991 Aug;78(2):161–170. [PubMed] [Google Scholar]
  100. Ziel H. K., Finkle W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167–1170. doi: 10.1056/NEJM197512042932303. [DOI] [PubMed] [Google Scholar]
  101. de Waard F. Breast cancer incidence and nutritional status with particular reference to body weight and height. Cancer Res. 1975 Nov;35(11 Pt 2):3351–3356. [PubMed] [Google Scholar]
  102. van Landeghem A. A., Poortman J., Nabuurs M., Thijssen J. H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985 Jun;45(6):2900–2906. [PubMed] [Google Scholar]
  103. von Schoultz E., Johansson H., Wilking N., Rutqvist L. E. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol. 1995 Feb;13(2):430–434. doi: 10.1200/JCO.1995.13.2.430. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES